BioCentury | Feb 18, 2021
Management Tracks

Day One names York COO, CFO; plus moves at Coherus, Antios, ArsenalBio, Affinia, Artelo and more

...NASDAQ:PRQR); and Centeno was SVP of regulatory, quality and U.S. operations at Epigenomics AG (Xetra:ECX; OTCQX:EPGNY).Maxwell...
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...officer, plans to step down from his role in January.Aquestive Therapeutics Inc. (NASDAQ:AQST) announced John Maxwell...
...company at year-end. Ernie Toth, who was most recently CFO at EHE Health, will succeed Maxwell...
BioCentury | Dec 10, 2020
Deals

Late in a year of cancer deals, Gilead spends $1B+ to add an antiviral for HDV

...$21 billion purchase of Immunomedics Inc. in September, Gilead’s largest M&A deal ever.MYR’s investors included Maxwell...
BioCentury | Apr 21, 2017
Clinical News

SQ109: Ph IIb/III data

...Russia and the Commonwealth of Independent States under a 2011 deal between Russian financial firm Maxwell...
...BioCentury, April 10, 2006 & May 2, 2011 ). Infectex is a portfolio company of Maxwell...
BioCentury | Jan 3, 2017
Distillery Techniques

Drug platforms

...School, Worcester, Mass. email: erik.sontheimer@umassmed.edu CONTACT: Karen L. Maxwell, University of Toronto, Toronto, Ontario email: karen.maxwell@utoronto.ca...
BioCentury | Dec 3, 2015
Translation in Brief

IL-17A's autoimmune dichotomy

...tight junctions." Lee, J., et al. "Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability." Immunity (2015); Maxwell...
BioCentury | Nov 5, 2015
Distillery Techniques

Techniques: Mouse model of Crohn's disease with intestinal epithelium barrier disruption

...disease with intestinal epithelium barrier disruption LICENSING STATUS: Patent and licensing status unavailable PUBLICATION DETAILS: Maxwell...
BioCentury | Nov 10, 2014
Clinical News

MBC-11: Phase I started

...from cancer. Osteros has exclusive, worldwide rights to develop and commercialize MBC-11 from MBC Pharma. Maxwell...
BioCentury | Aug 11, 2014
Clinical News

AHRO-001: Phase Ib started

...AtheroNova said partner CardioNova, a subsidiary of Maxwell Biotech, expanded a double-blind, placebo-controlled, Russian Phase I...
...Phase II trials in Russia (see BioCentury, Dec. 16, 2013). AtheroNova Inc. (OTCBB:AHROD), Irvine, Calif. Maxwell...
BioCentury | Aug 11, 2014
Clinical News

MM-D37K: Phase I/IIa started

...with advanced solid malignancies, including glioblastoma and gastrointestinal tumors. MetaMax is a portfolio company of Maxwell...
Items per page:
1 - 10 of 30
BioCentury | Feb 18, 2021
Management Tracks

Day One names York COO, CFO; plus moves at Coherus, Antios, ArsenalBio, Affinia, Artelo and more

...NASDAQ:PRQR); and Centeno was SVP of regulatory, quality and U.S. operations at Epigenomics AG (Xetra:ECX; OTCQX:EPGNY).Maxwell...
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...officer, plans to step down from his role in January.Aquestive Therapeutics Inc. (NASDAQ:AQST) announced John Maxwell...
...company at year-end. Ernie Toth, who was most recently CFO at EHE Health, will succeed Maxwell...
BioCentury | Dec 10, 2020
Deals

Late in a year of cancer deals, Gilead spends $1B+ to add an antiviral for HDV

...$21 billion purchase of Immunomedics Inc. in September, Gilead’s largest M&A deal ever.MYR’s investors included Maxwell...
BioCentury | Apr 21, 2017
Clinical News

SQ109: Ph IIb/III data

...Russia and the Commonwealth of Independent States under a 2011 deal between Russian financial firm Maxwell...
...BioCentury, April 10, 2006 & May 2, 2011 ). Infectex is a portfolio company of Maxwell...
BioCentury | Jan 3, 2017
Distillery Techniques

Drug platforms

...School, Worcester, Mass. email: erik.sontheimer@umassmed.edu CONTACT: Karen L. Maxwell, University of Toronto, Toronto, Ontario email: karen.maxwell@utoronto.ca...
BioCentury | Dec 3, 2015
Translation in Brief

IL-17A's autoimmune dichotomy

...tight junctions." Lee, J., et al. "Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability." Immunity (2015); Maxwell...
BioCentury | Nov 5, 2015
Distillery Techniques

Techniques: Mouse model of Crohn's disease with intestinal epithelium barrier disruption

...disease with intestinal epithelium barrier disruption LICENSING STATUS: Patent and licensing status unavailable PUBLICATION DETAILS: Maxwell...
BioCentury | Nov 10, 2014
Clinical News

MBC-11: Phase I started

...from cancer. Osteros has exclusive, worldwide rights to develop and commercialize MBC-11 from MBC Pharma. Maxwell...
BioCentury | Aug 11, 2014
Clinical News

AHRO-001: Phase Ib started

...AtheroNova said partner CardioNova, a subsidiary of Maxwell Biotech, expanded a double-blind, placebo-controlled, Russian Phase I...
...Phase II trials in Russia (see BioCentury, Dec. 16, 2013). AtheroNova Inc. (OTCBB:AHROD), Irvine, Calif. Maxwell...
BioCentury | Aug 11, 2014
Clinical News

MM-D37K: Phase I/IIa started

...with advanced solid malignancies, including glioblastoma and gastrointestinal tumors. MetaMax is a portfolio company of Maxwell...
Items per page:
1 - 10 of 30